药物治疗系统性轻链型淀粉样变性的心血管毒性  

Cardiovascular toxicity in treatment of patients with systemic light chain amyloidosis

作　　者：叶雨洁(综述) 黄湘华(审校) YE Yujie;HUANG Xianghua(National Clinical Research center for Kidney Diseases,Jinling Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210016,China)

机构地区：[1]南京大学医学院附属金陵医院(东部战区总医院)国家肾脏疾病临床医学研究中心,南京210016

出　　处：《肾脏病与透析肾移植杂志》2024年第3期259-263,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：国家自然科学基金面上项目(82270767)。

摘　　要：近年来,系统性轻链型(AL型)淀粉样变性治疗药物的发展与应用极大改善了患者的生存率,但这些药物的相关副作用,特别是心脏毒副作用,严重影响了患者的生活质量及生存率。因此,预防与药物治疗相关的心血管毒性,监测心血管并发症并及时处理具有重要意义。本文就治疗AL型淀粉样变性的药物所致心血管不良反应作一综述。In recent years,the development and application of therapeutic drugs for systemic light chain(AL)amyloidosis have greatly improved the survival rate of AL patients.However,the related side effects of these drugs,especially cardiac toxicity,seriously affect the quality of life and survival rate of patients.Therefore,the prevention and treatment of cardiovascular toxicity,monitoring of cardiovascular complications,and timely management are of great significance.This article provides a review of cardiovascular adverse reactions caused by therapeutic drugs for AL type amyloidosis.

关 键 词：系统性轻链型淀粉样变性 心脏毒性 治疗 

分 类 号：R597.2[医药卫生—内科学] R692[医药卫生—临床医学]